170 related articles for article (PubMed ID: 36063200)
1. Venetoclax combined with decitabine and HAAG regimen: a novel salvage strategy for relapsed/refractory T-cell acute lymphoblastic leukaemia.
Zhu Y; Dai Y; Tang X
Ann Hematol; 2022 Nov; 101(11):2525-2528. PubMed ID: 36063200
[No Abstract] [Full Text] [Related]
2. Venetoclax and decitabine in refractory TP53-mutated early T-cell precursor acute lymphoblastic leukemia.
Kong J; Chen N; Li M; Zhang J; Wu X; Zong L; Wu D; Song B; Qiu H
Ann Hematol; 2022 Mar; 101(3):697-699. PubMed ID: 33954816
[No Abstract] [Full Text] [Related]
3. Venetoclax combined with azacitidine as an effective and safe salvage regimen for relapsed or refractory T-cell acute lymphoblastic leukemia: a case series.
Wan CL; Zou JY; Qiao M; Yin J; Shen XD; Qiu QC; Liu SB; Xue SL
Leuk Lymphoma; 2021 Dec; 62(13):3300-3303. PubMed ID: 34323656
[No Abstract] [Full Text] [Related]
4. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
[TBL] [Abstract][Full Text] [Related]
5. Venetoclax and Decitabine in Pediatric Refractory T-cell Lymphoblastic Lymphoma.
Baig MU; Rytting M; Roth M; Morani AC; Nunez C; Lin P; Cuglievan B
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e991-e996. PubMed ID: 33480649
[TBL] [Abstract][Full Text] [Related]
6. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
[TBL] [Abstract][Full Text] [Related]
7. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.
Candoni A
Lancet Haematol; 2024 Apr; 11(4):e245-e246. PubMed ID: 38452789
[No Abstract] [Full Text] [Related]
8. [Clinical efficacy and safety of venetoclax combined with multidrug chemotherapy in the treatment of 15 patients with relapsed or refractory early T-cell precursor acute lymphoblastic leukemia].
Kong JY; Zong LH; Pu Y; Liu Y; Kong X; Li MY; Zhang J; Song BQ; Xue SL; Tang XW; Qiu HY; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2023 Aug; 44(8):649-653. PubMed ID: 37803838
[No Abstract] [Full Text] [Related]
9. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
[No Abstract] [Full Text] [Related]
10. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
[TBL] [Abstract][Full Text] [Related]
11. Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
Arora S; Vachhani P; Bachiashvili K; Jamy O
Leuk Lymphoma; 2021 Sep; 62(9):2292-2294. PubMed ID: 33691573
[No Abstract] [Full Text] [Related]
12. Relapsed/refractory early T-cell precursor acute lymphoblastic leukemia was salvaged by venetoclax plus HAG regimen.
Zhang X; Li J; Jin J; Yu W
Ann Hematol; 2020 Feb; 99(2):395-397. PubMed ID: 31879788
[No Abstract] [Full Text] [Related]
13. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
[No Abstract] [Full Text] [Related]
14. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
[No Abstract] [Full Text] [Related]
15. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
DiNardo CD
Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
[No Abstract] [Full Text] [Related]
16. Venetoclax plus decitabine induced complete remission with molecular response in acute myeloid leukemia relapsed after hematopoietic stem cell transplantation.
Andreani G; Dragani M; Serra A; Nicoli P; De Gobbi M; Cilloni D
Am J Hematol; 2019 Feb; 94(2):E48-E50. PubMed ID: 30431666
[No Abstract] [Full Text] [Related]
17. Venetoclax and azacytidine combination is an effective bridge to transplant strategy in relapsed/refractory acute myeloid leukemia patients.
Zappasodi P; Brociner M; Merati G; Nizzoli ME; Roncoroni E; Boveri E; Castagnola C; Arcaini L
Ann Hematol; 2021 Apr; 100(4):1111-1113. PubMed ID: 33175198
[No Abstract] [Full Text] [Related]
18. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia.
Aldoss I; Yang D; Aribi A; Ali H; Sandhu K; Al Malki MM; Mei M; Salhotra A; Khaled S; Nakamura R; Snyder D; O'Donnell M; Stein AS; Forman SJ; Marcucci G; Pullarkat V
Haematologica; 2018 Sep; 103(9):e404-e407. PubMed ID: 29545346
[No Abstract] [Full Text] [Related]
19. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
[No Abstract] [Full Text] [Related]
20. Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia.
Richard-Carpentier G; Jabbour E; Short NJ; Rausch CR; Savoy JM; Bose P; Yilmaz M; Jain N; Borthakur G; Ohanian M; Alvarado Y; Rytting M; Kebriaei P; Konopleva M; Kantarjian H; Ravandi F
Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):212-218. PubMed ID: 32035785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]